Restarting Suboxone After One Week Off: Dosing Protocol
After one week off buprenorphine, restart with standard induction dosing: begin with 4–8 mg sublingual buprenorphine/naloxone on day 1, followed by 16 mg on day 2, then continue with 16 mg daily for maintenance. 1
Rationale for Standard Induction Approach
After a one-week abstinence period, the patient's opioid receptors are no longer occupied by buprenorphine, making this functionally equivalent to a new induction rather than a simple dose resumption. The FDA-approved protocol provides the safest and most effective pathway:
- Day 1: Administer 8 mg of buprenorphine (Subutex preferred for initial induction) 1
- Day 2: Increase to 16 mg of buprenorphine 1
- Day 3 onward: Switch to Suboxone (buprenorphine/naloxone combination) at 16 mg daily for maintenance 1
Critical Timing Considerations
Do not initiate buprenorphine until objective withdrawal signs appear. 2 After one week off buprenorphine, the patient should not experience significant withdrawal from buprenorphine itself (given its long half-life), but if they have used other opioids during this week-long gap, you must wait for withdrawal to manifest:
- Wait minimum 12–24 hours after last short-acting opioid use (e.g., heroin) 2, 1
- For fentanyl exposure specifically, many clinicians now extend this interval beyond 24 hours due to tissue accumulation 2
- Confirm moderate withdrawal using Clinical Opioid Withdrawal Scale (COWS ≥ 8) before first dose 2
Maintenance Dosing Strategy
Target 16 mg daily as the standard maintenance dose, with an effective therapeutic range of 12–24 mg daily. 1 However, emerging evidence supports flexibility:
- The 16 mg target dose is clinically effective for most patients 1
- Some patients may require doses up to 32 mg daily for optimal outcomes, particularly with fentanyl exposure 3
- A "hybrid strategy" of reaching minimum threshold dose (16 mg) then increasing in response to continued opioid use reduces relapse risk by 13% compared to fixed dosing 4
Key Clinical Pitfalls to Avoid
Precipitated withdrawal risk: If the patient used full-agonist opioids during the week off buprenorphine, premature dosing will displace these opioids and precipitate severe withdrawal. 2 Always document objective withdrawal signs before administering the first dose. 2
Inadequate dose escalation: Gradual induction over several days leads to high dropout rates during induction. 1 Achieve adequate maintenance dose (16 mg) as rapidly as possible—by day 2—to prevent undue withdrawal symptoms and treatment discontinuation. 1
Underdosing concerns: The traditional 16 mg "target" may be insufficient for patients with high tolerance or fentanyl exposure. 3 Monitor for continued opioid use, craving, and withdrawal symptoms, and be prepared to increase to 24–32 mg if clinically indicated. 4, 3
Monitoring and Safety
- Ensure naloxone is readily available during induction 2
- Use validated withdrawal scales (COWS) to document readiness for induction 2
- Instruct patient to hold tablets under tongue until dissolved; swallowing reduces bioavailability 1
- Once-daily dosing is associated with better outcomes (84% negative urine drug screens) compared to divided dosing (74% negative screens) 5